{"id":"drug-placebo-administered-sc","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1397913","moleculeType":"Small molecule","molecularWeight":"339.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is administered to serve as a comparator arm in randomized controlled trials, allowing researchers to isolate the true therapeutic effect of an investigational drug from placebo response and natural disease progression. The subcutaneous (SC) route of administration matches the delivery method of the active comparator drug being studied.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:03.623Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06963827","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-15","conditions":"Kidney Disease","enrollment":347},{"nctId":"NCT05065216","phase":"PHASE2, PHASE3","title":"Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","status":"RECRUITING","sponsor":"DiaMedica Therapeutics Inc","startDate":"2021-11-07","conditions":"Acute Stroke, Ischemic Stroke, Stroke","enrollment":728},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT05271409","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-08-30","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","enrollment":152},{"nctId":"NCT04936308","phase":"PHASE3","title":"Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Arthritis, Psoriatic","enrollment":453},{"nctId":"NCT07462130","phase":"PHASE1, PHASE2","title":"An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-03-01","conditions":"Thyroid Eye Disease","enrollment":74},{"nctId":"NCT06619990","phase":"PHASE1, PHASE2","title":"Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"Xencor, Inc.","startDate":"2024-10-10","conditions":"Ulcerative Colitis (UC)","enrollment":270},{"nctId":"NCT05503264","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-09-27","conditions":"NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis","enrollment":152},{"nctId":"NCT06864104","phase":"PHASE2","title":"A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kardigan, Inc.","startDate":"2025-04-10","conditions":"Hypertension","enrollment":206},{"nctId":"NCT07010159","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study of KPL-387 in Recurrent Pericarditis","status":"RECRUITING","sponsor":"Kiniksa Pharmaceuticals International, plc","startDate":"2025-07-25","conditions":"Pericarditis, Pericarditis Acute, Recurrent Pericarditis","enrollment":165},{"nctId":"NCT07172022","phase":"PHASE2","title":"A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-03-16","conditions":"Antiphospholipid Syndrome","enrollment":""},{"nctId":"NCT06272487","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2024-02-29","conditions":"High Cardiovascular Risk, Hypertension","enrollment":375},{"nctId":"NCT07431827","phase":"PHASE3","title":"MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07181109","phase":"PHASE3","title":"Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2025-09-22","conditions":"High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk","enrollment":11000},{"nctId":"NCT05819658","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2023-06-14","conditions":"Progressive Supranuclear Palsy","enrollment":78},{"nctId":"NCT05519475","phase":"PHASE2","title":"A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-02-09","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH)","enrollment":90},{"nctId":"NCT03398135","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-28","conditions":"Ulcerative Colitis (UC)","enrollment":1242},{"nctId":"NCT05361733","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Xfibra, Inc.","startDate":"2026-01-15","conditions":"Focus of the Study: Safety of XFB19","enrollment":40},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT06407934","phase":"PHASE3","title":"A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-05-08","conditions":"Dermatitis Atopic","enrollment":1541},{"nctId":"NCT03705234","phase":"PHASE3","title":"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2018-10-30","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":16124},{"nctId":"NCT06060067","phase":"PHASE3","title":"A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Healthy Volunteers","enrollment":480},{"nctId":"NCT07245771","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity","status":"RECRUITING","sponsor":"Ikaria Bioscience Pty Ltd","startDate":"2025-11-04","conditions":"Obesity &Amp; Overweight","enrollment":104},{"nctId":"NCT02747927","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-26","conditions":"Healthy Volunteers","enrollment":20099},{"nctId":"NCT04743791","phase":"PHASE4","title":"Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sally E. Wenzel MD","startDate":"2022-10-17","conditions":"Asthma","enrollment":30},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT06032546","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382","status":"TERMINATED","sponsor":"AbbVie","startDate":"2023-10-12","conditions":"Human Immuno-deficiency Virus (HIV) Disease","enrollment":163},{"nctId":"NCT05074433","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-10-25","conditions":"Immunocompromised","enrollment":66},{"nctId":"NCT04572841","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-11-12","conditions":"Sjögren's Syndrome, Sjogren's Syndrome","enrollment":84},{"nctId":"NCT06714955","phase":"PHASE1","title":"Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-10-21","conditions":"Non-diabetic Overweight or Obese","enrollment":30},{"nctId":"NCT06055361","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Brexogen Inc.","startDate":"2023-04-18","conditions":"Atopic Dermatitis","enrollment":45},{"nctId":"NCT02855268","phase":"PHASE2","title":"Study of Lademirsen (SAR339375) in Patients With Alport Syndrome","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2019-11-02","conditions":"Alport Syndrome","enrollment":43},{"nctId":"NCT06500429","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist","status":"COMPLETED","sponsor":"Neurogastrx, Inc.","startDate":"2024-06-24","conditions":"Overweight and Obesity, Healthy","enrollment":120},{"nctId":"NCT05189210","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)","status":"COMPLETED","sponsor":"GemVax & Kael","startDate":"2022-10-05","conditions":"Mild to Moderate Alzheimer's Disease","enrollment":199},{"nctId":"NCT07040930","phase":"PHASE1","title":"Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05462522","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2023-01-16","conditions":"Systemic Sclerosis","enrollment":56},{"nctId":"NCT04994509","phase":"PHASE3","title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-08-30","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":5368},{"nctId":"NCT06665035","phase":"PHASE3","title":"A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-06-16","conditions":"Dengue Fever","enrollment":212},{"nctId":"NCT06606821","phase":"PHASE4","title":"The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease","status":"RECRUITING","sponsor":"Tina Vilsbøll","startDate":"2024-10-01","conditions":"Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity","enrollment":124},{"nctId":"NCT06526182","phase":"PHASE3","title":"A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2024-07-03","conditions":"Dermatitis, Atopic, Eczema","enrollment":520},{"nctId":"NCT06974825","phase":"PHASE2","title":"A Study of BGM0504 in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2023-08-30","conditions":"Type 2 Diabetes","enrollment":67},{"nctId":"NCT04957485","phase":"PHASE2","title":"Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS","status":"ACTIVE_NOT_RECRUITING","sponsor":"SIGA Technologies","startDate":"2022-04-05","conditions":"Smallpox","enrollment":100},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT05454410","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-13","conditions":"Treatment-Resistant Depression","enrollment":60},{"nctId":"NCT05079230","phase":"PHASE3","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-07","conditions":"Acute Myeloid Leukemia","enrollment":378},{"nctId":"NCT04753697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-02-22","conditions":"Eosinophilic Esophagitis","enrollment":430},{"nctId":"NCT03761537","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-13","conditions":"Atopic Dermatitis","enrollment":277},{"nctId":"NCT05891236","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2023-08-14","conditions":"Malaria","enrollment":61},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT05203237","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Safety and Tolerability of VK2735","status":"COMPLETED","sponsor":"Viking Therapeutics, Inc.","startDate":"2021-12-14","conditions":"Weight Loss, NASH","enrollment":92},{"nctId":"NCT05902325","phase":"PHASE4","title":"Identifying Predictors Of Response To Mepolizumab In CRSwNP","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-10-03","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":36},{"nctId":"NCT06716203","phase":"PHASE3","title":"A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-12-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":207},{"nctId":"NCT04615273","phase":"PHASE3","title":"A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Ascendis Pharma Endocrinology Division A/S","startDate":"2020-12-03","conditions":"Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency","enrollment":264},{"nctId":"NCT06774664","phase":"PHASE1, PHASE2","title":"A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-01","conditions":"IgA Nephropathy","enrollment":99},{"nctId":"NCT04576988","phase":"PHASE3","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-01-25","conditions":"Pulmonary Arterial Hypertension","enrollment":324},{"nctId":"NCT04555486","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients","status":"COMPLETED","sponsor":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","startDate":"2020-09-14","conditions":"Primary Hyperoxaluria Type 3","enrollment":6},{"nctId":"NCT04730804","phase":"PHASE1","title":"A Study of ALXN1830 in Healthy Adult Participants","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-03-17","conditions":"Healthy","enrollment":34},{"nctId":"NCT06055374","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis","status":"WITHDRAWN","sponsor":"Brexogen Inc.","startDate":"2024-05-01","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT04313881","phase":"PHASE3","title":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2020-09-09","conditions":"Myelodysplastic Syndromes","enrollment":539},{"nctId":"NCT00696800","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-27","conditions":"In Vitro Fertilization","enrollment":1509},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":"Infertility","enrollment":397},{"nctId":"NCT03847909","phase":"PHASE2","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-10-28","conditions":"Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases","enrollment":35},{"nctId":"NCT05347147","phase":"PHASE3","title":"A Trial to Determine the Efficacy and Safety of Presendin in IIH","status":"TERMINATED","sponsor":"Invex Therapeutics Ltd.","startDate":"2022-11-18","conditions":"Idiopathic Intracranial Hypertension","enrollment":14},{"nctId":"NCT03029442","phase":"PHASE4","title":"The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury","status":"TERMINATED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2017-04-01","conditions":"Secondary Osteoporosis, Spinal Cord Injury","enrollment":5},{"nctId":"NCT02737306","phase":"PHASE2","title":"A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation","status":"TERMINATED","sponsor":"CytoDyn, Inc.","startDate":"2017-05-14","conditions":"Graft Vs Host Disease","enrollment":11},{"nctId":"NCT05417269","phase":"PHASE1, PHASE2","title":"IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imcyse SA","startDate":"2022-04-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":150},{"nctId":"NCT03814187","phase":"PHASE3","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-16","conditions":"ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia","enrollment":3275},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT06118021","phase":"PHASE2","title":"A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-10-16","conditions":"Overweight and Obesity","enrollment":200},{"nctId":"NCT02760433","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2017-01-25","conditions":"Rheumatoid Arthritis","enrollment":368},{"nctId":"NCT04881760","phase":"PHASE2","title":"A Study of LY3437943 in Participants Who Have Obesity or Are Overweight","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-20","conditions":"Obesity, Overweight","enrollment":338},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT03197870","phase":"PHASE2","title":"The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2017-06-09","conditions":"Nonproliferative Diabetic Retinopathy","enrollment":167},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT00730392","phase":"PHASE1, PHASE2","title":"Etanercept in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2002-10","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT03416179","phase":"PHASE3","title":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-20","conditions":"Leukemia, Myeloid, Acute","enrollment":730},{"nctId":"NCT02028884","phase":"PHASE3","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-20","conditions":"Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)","enrollment":85},{"nctId":"NCT03851705","phase":"PHASE3","title":"A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-06","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":56},{"nctId":"NCT03385239","phase":"PHASE2","title":"Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)","status":"COMPLETED","sponsor":"Akcea Therapeutics","startDate":"2018-01-30","conditions":"Hypertriglyceridemia, Cardiovascular Diseases","enrollment":114},{"nctId":"NCT03546907","phase":"PHASE2","title":"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-07-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":343},{"nctId":"NCT05080049","phase":"PHASE3","title":"Erythropoietin to Improve Critical Care Patient Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2022-01-28","conditions":"Anemia, Intensive Care","enrollment":42},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT02552212","phase":"PHASE3","title":"Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-09","conditions":"Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA","enrollment":317},{"nctId":"NCT04590586","phase":"PHASE3","title":"Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-24","conditions":"COVID-19","enrollment":515},{"nctId":"NCT03390101","phase":"PHASE3","title":"An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-12-26","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":213},{"nctId":"NCT03376802","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-04-18","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT04666441","phase":"PHASE2","title":"COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-15","conditions":"COVID-19","enrollment":1149},{"nctId":"NCT03959553","phase":"PHASE2","title":"GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)","status":"WITHDRAWN","sponsor":"GemVax & Kael","startDate":"2019-09-01","conditions":"Moderate Alzheimer's Disease","enrollment":""},{"nctId":"NCT02130882","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05-19","conditions":"Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases","enrollment":20},{"nctId":"NCT00702624","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Pregnancy, Neonates","enrollment":113},{"nctId":"NCT00702546","phase":"","title":"Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12","conditions":"In Vitro Fertilization","enrollment":102},{"nctId":"NCT03700658","phase":"PHASE1","title":"A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-01-15","conditions":"Contraception","enrollment":27},{"nctId":"NCT04519437","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-26","conditions":"Healthy, Chronic Stable Illness","enrollment":974},{"nctId":"NCT04039503","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-08-30","conditions":"Type 2 Diabetes","enrollment":475},{"nctId":"NCT03051217","phase":"PHASE2, PHASE3","title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-21","conditions":"Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Drug: Placebo Administered SC","genericName":"Drug: Placebo Administered SC","companyName":"BrightGene Bio-Medical Technology Co., Ltd.","companyId":"brightgene-bio-medical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}